Amitriptyline Hydrochloride and Menveo

• Generic Name: amitriptyline
• Dosage Forms: n.a.
• Other Brand Names: Vanatrip, Elavil, Endep

Management of major depressive disorder.

Has been used in fixed combination with chlordiazepoxide in the management of depression associated with moderate to severe anxiety.

Management of moderate to severe anxiety and/or agitation (in fixed combination with perphenazine) in patients with depressed mood.

Management of severe anxiety and/or agitation (in fixed combination with perphenazine) in patients with depression.

Management of depression and anxiety (in fixed combination with perphenazine) in association with chronic physical disease.

Management of acute depressive episodes (in fixed combination with perphenazine) in patients with schizophrenia.

Second-line agent in attention deficit hyperactivity disorder (ADHD) patients unable to tolerate or unresponsive to stimulants; should be used only under close supervision.

Associated with a narrower margin of safety than some other therapeutic agents; use only if clearly indicated and with careful monitoring, including baseline and subsequent determinations of ECG and other parameters.

Medium to high efficacy for prophylaxis of migraine headache.

Equivocal efficacy for management of eating disorders (e.g., bulimia, anorexia nervosa); avoid use in underweight individuals and in those exhibiting suicidal ideation.

Has been used for the short-term management of acute depressive episodes in bipolar disorder.

TCAs associated with a greater risk of precipitating hypomania or manic episodes than other classes of antidepressants; should always be used in combination with a mood stabilizer (e.g., lithium).

Among the drugs of choice for the symptomatic treatment of postherpetic neuralgia.

Less effective for insomnia and associated with more serious adverse reactions than conventional hypnotics.

• Generic Name: meningococcal conjugate vaccine
• Dosage Forms: injection
• Other Brand Names: Menactra, Menveo

Menveo (meningococcal conjugate vaccine) is used to prevent meningococcal disease, an infection caused by meningococcal bacteria. These bacteria can infect the spinal cord and brain, causing meningitis that can be fatal. Meningococcal disease can also lead to permanent and disabling medical problems.

Meningococcal disease can spread from one person to another through small droplets of saliva that are expelled into the air when an infected person coughs or sneezes. The bacteria can also be passed through contact with objects the infected person has touched, such as a door handle or other surface. The bacteria can also be passed through kissing, or sharing a drinking glass or eating utensil with an infected person.

Meningococcal disease is more likely to occur in babies younger than 1 year, in young people ages 16 to 23 years, in anyone with a weak immune system, and in anyone exposed to an outbreak of the disease.

Menveo works by exposing you to a small dose of the bacteria or a protein from the bacteria, which causes your body to develop immunity to the disease. Menveo contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y).

Meningococcal vaccine will not treat an active meningococcal infection that has already developed in the body.

Menveo is for use in children and adults between the ages of 9 months and 55 years old.

Like any vaccine, Menveo may not provide protection from disease in every person.